ATE227120T1 - Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen - Google Patents

Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen

Info

Publication number
ATE227120T1
ATE227120T1 AT98921701T AT98921701T ATE227120T1 AT E227120 T1 ATE227120 T1 AT E227120T1 AT 98921701 T AT98921701 T AT 98921701T AT 98921701 T AT98921701 T AT 98921701T AT E227120 T1 ATE227120 T1 AT E227120T1
Authority
AT
Austria
Prior art keywords
testosterone
devices
precursor compounds
intravaginal administration
precursor
Prior art date
Application number
AT98921701T
Other languages
English (en)
Inventor
Clare Passmore
Claire Gilligan
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of ATE227120T1 publication Critical patent/ATE227120T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98921701T 1997-05-07 1998-05-07 Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen ATE227120T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (1)

Publication Number Publication Date
ATE227120T1 true ATE227120T1 (de) 2002-11-15

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921701T ATE227120T1 (de) 1997-05-07 1998-05-07 Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen

Country Status (15)

Country Link
US (1) US6416780B1 (de)
EP (1) EP0981327B1 (de)
JP (1) JP2001524124A (de)
CN (1) CN1184957C (de)
AT (1) ATE227120T1 (de)
AU (1) AU741482B2 (de)
CA (1) CA2288046C (de)
DE (1) DE69809222T2 (de)
DK (1) DK0981327T3 (de)
ES (1) ES2187024T3 (de)
IL (1) IL132702A0 (de)
NO (1) NO995419L (de)
NZ (1) NZ501236A (de)
PT (1) PT981327E (de)
WO (1) WO1998050016A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003080019A1 (en) * 2002-03-27 2003-10-02 Galen (Chemicals) Limited Intravaginal reservoir drug delivery devices
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
PL2359807T3 (pl) 2008-02-04 2017-12-29 Ferring B.V. Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9114111B2 (en) 2011-01-10 2015-08-25 Allergan, Inc. Methods for sustained treatment of bladder pain and irritative voiding
AU2012211960B2 (en) 2011-02-04 2016-12-01 Taris Biomedical Llc Implantable device for controlled release of low solubility drug
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (de) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Verzögerte freisetzung von wirkstoffen zur behandlung von glaukom oder okularer hypertonie
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2970434B1 (de) 2013-03-15 2018-12-05 The Regents of The University of California Potenter kunitz-inhibitor der fibrinolyse mit dualer reaktivität
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
CN113413393B (zh) 2013-08-19 2025-03-04 塔里斯生物医药公司 多单元药物递送装置和方法
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
US9820994B2 (en) * 2014-06-28 2017-11-21 Laboratorios Andromaco S.A. Cerclage pessary containing progesterone of prolonged, sustained, and continuous release useful for prevention of preterm birth
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
MX376974B (es) 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
JP2021530541A (ja) 2018-07-27 2021-11-11 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. てんかんの治療方法
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
CA3129722A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
CA3232237A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinyl derivatives as sodium channel activators
CN120265625A (zh) 2021-09-24 2025-07-04 泽农医药公司 作为钠通道活化剂的吡啶基乙酰胺衍生物
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
GB2079158B (en) * 1980-06-09 1985-01-09 Ahi Operations Ltd Intra-vaginal devices
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
EP0981327A2 (de) 2000-03-01
ES2187024T3 (es) 2003-05-16
DE69809222T2 (de) 2003-08-14
CA2288046A1 (en) 1998-11-12
NO995419D0 (no) 1999-11-05
US6416780B1 (en) 2002-07-09
CN1255056A (zh) 2000-05-31
EP0981327B1 (de) 2002-11-06
PT981327E (pt) 2003-02-28
CA2288046C (en) 2006-10-03
CN1184957C (zh) 2005-01-19
AU7446998A (en) 1998-11-27
WO1998050016A2 (en) 1998-11-12
NZ501236A (en) 2002-02-01
DE69809222D1 (de) 2002-12-12
IL132702A0 (en) 2001-03-19
DK0981327T3 (da) 2003-03-10
WO1998050016A3 (en) 1999-02-04
NO995419L (no) 2000-01-07
AU741482B2 (en) 2001-11-29
JP2001524124A (ja) 2001-11-27

Similar Documents

Publication Publication Date Title
ATE227120T1 (de) Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen
AU1227899A (en) Osmotic medicament releasing system
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
CA2298245A1 (en) Matrix controlled release device
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
EP1504758A3 (de) Formulierungen mit kontrollierter Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose.
PT1238660E (pt) Distribuicao sustentada de um agente activo utilizando um sistema implantavel
BR0014929A (pt) Dispositivo para distribuição de medicamento, e, processo para distribuir um agente farmaceuticamente ativo para um tecido alvo dentro de um corpo
EP1466606A3 (de) Verwendung von Inosine zur Herstellung eines Medikamentes zur Stimulierung des Axonwachstums von ZNS-Neuronen
PT1017391E (pt) Formulacao de comprimidos de libertacao prolongada para tratar a doenca de parkinson
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
BR9902528A (pt) Sistema implantável e implante destinado à administração subcutânea ou local
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
IL134591A0 (en) Medicament formulation with a controlled release of an active agent
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
MY129726A (en) Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
EP1106609A3 (de) Aminoalkohol-Derivat und Medikament, das dieses Derivat enthält
NZ309697A (en) Novel formulation for peptide release
NZ324674A (en) Rapid release tablet comprising tolfenamic acid, alginic acid and a superdisintegrant
ATE236621T1 (de) Niedrig dosierte tabletten, und verfahren zur herstellung
ZA9711660B (en) Therapeutic agent and treatment for canine intractable dermatitis.
PT8662T (pt) Doseador para distribuir um medicamento inoforo aplicado em especial para tratamento de animais
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0981327

Country of ref document: EP

REN Ceased due to non-payment of the annual fee